fbpx Aiming for the top of the “recovery tree” | Progress In Mind

Aiming for the top of the “recovery tree”

It is a powerful image: full functional recovery from depression and enhanced quality of life are the topmost branches of the recovery tree. Helping patients emerge into the light means assessing root causes, and addressing issues of mood, physical functioning and cognition as they make their ascent. Success also involves reducing the risk of a fall, in the form of relapse.

For patients with major depressive disorder (MDD), a return to role function and activities with family and friends, and work and education is the highest priority.1-4 Clinicians and patients may differ to some extent when assessing the goals of therapy, but there has undoubtedly been evolution in our collective understanding that full functional recovery is what constitutes a good outcome – and this is exemplified by the Canadian Network for Mood and Anxiety Treatment guideline.1

Diane McIntosh (University of British Columbia, Vancouver, Canada; and a member of CANMAT) focused on the importance of achieving this patient-centered treatment goal in her presentation at a satellite meeting during ECNP Virtual 2020.

Early restoration of function is a window of opportunity

 

What the studies tell us

Getting patients to feel well in the first 8-12 weeks involves establishing a therapeutic alliance, education and support for self-management, the selection and delivery of evidence-based treatment, and the monitoring of progress,1 Professor McIntosh argued. Keeping patients well means full restoration of function, treatment of comorbidities, and preventing recurrence.

 

New tool helps patients set goals and track progress

Patient-centered care should be our aim, and the way to achieve it is the systematic measurement of patients’ progress towards goals that they themselves define, argued Mark Opler (WCG MedAvante-ProPhase Inc., New York, USA), who also contributed to the satellite meeting. 

The Goal Attainment Scale for Depression (GAS-D) has been devised to help  track an individual’s progress towards restored functioning.10  Individualized goals are set by collaborative discussion of a patient’s experience of depression and its impact on their life. 

What matters most to the individual patient is vital

In a study of 122 patients with MDD, participants identified specific goals in relation to general, physical, social and cognitive wellbeing and completed the GAS-D over twelve weeks of antidepressant therapy.

The majority of patients achieved their personalized recovery goals within 12 weeks.11  The mean baseline GAS-D score of 23.6 rose to 41.8 at week 6 and 50.5 at week 12. At both time points, improvements from baseline were statistically significant.

 

Educational financial support for this satellite symposium at ECNP Virtual 2020 was provided by H. Lundbeck A/S

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

This content does not necessarily represent the opinion of ECNP.
References

1. Lam RW et al. Can J Psychiatry 2016;61:510-23

2. Oluboka OJ et al. ‎Int J Neuropsychopharmacol 2018;21:128-44

3. Battle CL et al. J Psychiatr Pract 2010;16:425-30

4. Zimmerman M et al. Am J Psychiatry 2006;163:148-50

5. Rush AJ et al. Am J Psychiatry 2006;163:1905-17

6. Keitner GI, Mansfield AK. Psychiatr Clin North Am 2012;35:249-65

7. Trivedi MH et al. Int Clin Psychopharmacol 2009;24:133-8

8. Nierenberg AA, DeCecco LM. J Clin Psychiatry 2001;62(Suppl 16):5-9

9. Judd LL et al. J Clin Psychiatry 2016;77:1065-73

10. McCue M et al. Neurol Ther 2019;8:167-76

11. McCue M et al. Poster presented at the 2018 Psych Congress, abs 232

You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country